You are here

Article Text

Article menu
Download PDFPDF
PostScript
Letter
Is sitagliptin effective for the treatment of COVID-19?
  1. Hasan Memiş,
  2. Ahmet Çakır,
  3. Mefküre DURMUŞ,
  4. Selim GÖK,
  5. Ömer Faruk Bahçeciȯğlu
  1. Clinical Pharmacy, Inonu University, Malatya, Turkey
  1. Correspondence to Ömer Faruk Bahçeciȯğlu, Clinical Pharmacy, İnönü Üniversitesi, 44280 Malatya, Turkey; omerfb92{at}hotmail.com

https://doi.org/10.1136/ejhpharm-2021-002702

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Cluster of differantiation 26 (CD26) plays an important role in chronic graft versus host disease (GVHD), psoriasis, diabetes, haematological and solid cancers. In addition, S1, the spike protein of Middle East respiratory syndrome coronavirus, has been shown to enter human host cells using CD26, also known as dipeptidyl peptidase-4 (DPP-4), as a functional receptor.1 In a molecular docking study, it was determined that the S1 domain of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spike protein could potentially interact with CD26, an important immunoregulatory factor for hijacking and virulence.2

    In a retrospective observational case-control study, 338 patients with type 2 diabetes …

    View Full Text

    Footnotes

    • Contributors All authors contributed equally to the writing of the letter.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; internally peer reviewed.